Hetero Labs Limited Dapagliflozin Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Dapagliflozin Export Records India — #8 Exporter, 49 Shipments, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Dapagliflozin

India Pharmaceutical Trade Intelligence

$49.5M254 Suppliers113 CountriesHS 30049099

ExportsIndia → CANADA25.9%India → IRAQ17.2%

ImportsGERMANY → India$59.4K BRAZIL → India$38.8K

#1 Supplier: AJANTA PHARMA

Hetero Labs Limited — Dapagliflozin Exporter #8 | $1.2M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Dapagliflozin Exporter Profile

Indian Pharmaceutical Exporter · #8 for Dapagliflozin · $1.2M export value · DGFT Verified

Hetero Labs Limited is the #8 Indian exporter of Dapagliflozin with $1.2M in export value and 49 verified shipments. Hetero Labs Limited holds a 2.5% market share in Dapagliflozin exports across 11 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Dapagliflozin Export Profile: Buyers & Destinations

Hetero Labs Limited Dapagliflozin export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Dapagliflozin?

Country	Value	Shipments	Share
SAUDI ARABIA	$289.3K	15	32.8%
INDONESIA	$256.3K	10	29.0%
MEXICO	$93.1K	2	10.5%
UZBEKISTAN	$72.2K	5	8.2%
MALAYSIA	$42.9K	5

Who Are the Top Buyers of Dapagliflozin from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	BRAZIL	$223.6K	13
AMAROX PHARMA S A DE C V	MEXICO	$93.1K	2
SAUDI AMAROX FOR INDUSTRY COMPANY	SAUDI ARABIA	$89.4K	5
TO THE ORDER	INDONESIA	$79.9K	3
LLC MEROS PHARM	UZBEKISTAN	$72.2K	5
PT. AMAROX PHARMA GLOBAL	INDONESIA	$66.6K	2
PT AMAROX PHARMA GLOBAL	INDONESIA	$66.3K	2
M S TO THE ORDER OFSAUDI AMAROX FOR INDUSTRY	SAUDI ARABIA	$39.2K	3
CAMBER LABORATORIES SDN BHD	MALAYSIA	$31.7K	3
TO THE ORDER OF.,	SAUDI ARABIA	$30.6K	1

Hetero Labs Limited supplies Dapagliflozin to 17 buyers globally. The largest buyer is TO THE ORDER OF (BRAZIL), followed by AMAROX PHARMA S A DE C V (MEXICO) and SAUDI AMAROX FOR INDUSTRY COMPANY (SAUDI ARABIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Dapagliflozin Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
DAPAZOX DAPAGLIFLOZIN TABLET	$181.1K	11
DAPXIGA 10MG DAPAGLIFLOZIN 10MG TABS 22 120 PACKS OF 30 s TABLETS EACH AS PERINVOICE	$82.3K	2
DAPXIGA DAPAGLIFLOZIN TABLET	$63.3K	4
DAPAZOX DAPAGLIFLOZIN	$51.6K	2
DAPAGLIFLOZIN 10MG TABLET PACK 40104 X28 S 1122912 NOS	$50.0K	1
DAGLIFOR DAPAGLIFLOZIN TABLET	$47.8K	3
DAPAZOX DAPAGLIFLOZIN 10MG TABLET 10S	$43.3K	2
DAPAGLIFLOZIN 10MG TABLET 28S 23820 PACK X 28S 666960 NOS	$43.1K	1
GLYXIGA DAPAGLIFLOZIN	$41.2K	1
DAPAZOX DAPAGLIFLOZIN TABS	$40.8K	2

Hetero Labs Limited exports 29 distinct Dapagliflozin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DAPAZOX DAPAGLIFLOZIN TABLET with 11 shipments worth $181.1K.

How Does Hetero Labs Limited Compare to Nearest Dapagliflozin Exporters?

Exporters ranked immediately above and below #8 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
7	WATSON PHARMA PRIVATE LIMITED	$1.8M	63	6	$29.3K
6	MACLEODS PHARMACEUTICALS LTD	$1.7M	34	8	$50.0K
8	HETERO LABS LIMITED ★	$1.2M	49	11	$24.8K
9	SANDOZ PRIVATE LIMITED	$1.1M	44	3	$25.9K
11	MSN LABORATORIES PRIVATE LIMITED	$825.0K	42	8	$19.6K

Hetero Labs Limited ranks #8 among 254 Indian Dapagliflozin exporters. Average shipment value of $24.8K compared to the market average of $135.5K. The closest competitors by value are WATSON PHARMA PRIVATE LIMITED and MACLEODS PHARMACEUTICALS LTD.

Which Indian Ports Ship Dapagliflozin Exports?

Port	Shipments	% Share
SAHAR AIR	1,003	19.7%
SAHAR AIR CARGO ACC (INBOM4)	791	15.5%
DELHI AIR CARGO ACC (INDEL4)	761	14.9%
DELHI AIR	612	12.0%
Bombay Air	194	3.8%
BANGALORE ACC (INBLR4)	189	3.7%
BANGALORE AIR	160	3.1%
NHAVA SHEVA SEA (INNSA1)	136	2.7%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Dapagliflozin Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Dapagliflozin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 49 individual customs records matching Hetero Labs Limited exporting Dapagliflozin, covering 29 formulations to 12 countries via 17 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 113+ countries, 502+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Dapagliflozin

Dapagliflozin

Hetero Labs Limited — Dapagliflozin Exporter Profile

Hetero Labs Limited — Dapagliflozin Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Dapagliflozin?

Who Are the Top Buyers of Dapagliflozin from Hetero Labs Limited?

What Is India's Total Dapagliflozin Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Dapagliflozin Exports?

How Does Hetero Labs Limited Compare to Other Indian Dapagliflozin Exporters?

What Dapagliflozin Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Dapagliflozin to Key Markets

Mexico — COFEPRIS

How Does Hetero Labs Limited Compare to Nearest Dapagliflozin Exporters?

Which Indian Ports Ship Dapagliflozin Exports?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Dapagliflozin Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Dapagliflozin Export Data from Hetero Labs Limited

Dapagliflozin Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source